Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Emergent BioSolutions Inc (NYSE:EBS)

31.53
Delayed Data
As of 4:02pm ET
 +3.77 / +13.58%
Today’s Change
25.51
Today|||52-Week Range
41.91
-16.56%
Year-to-Date
Why Emergent Biosolutions Inc Surged Higher Today
4:33pm / MotleyFool.com - Paid Partner Content
Ligand (LGND) Inks Deal with TeneoBio for OmniAb Technology
Sep 19 / Zacks.com - Paid Partner Content

Today’s Trading

Previous close27.76
Today’s open29.42
Day’s range29.39 - 31.80
Volume1,400,402
Average volume (3 months)674,541
Market cap$1.1B
Dividend yield--
Data as of 4:02pm ET, 09/30/2016

Growth & Valuation

Earnings growth (last year)+60.23%
Earnings growth (this year)-28.90%
Earnings growth (next 5 years)+21.00%
Revenue growth (last year)+16.14%
P/E ratio22.0
Price/Sales3.62
Price/Book1.66

Competitors

 Today’s
change
Today’s
% change
AERIAerie Pharmaceutical...+0.04+0.11%
EGRXEagle Pharmaceutical...+0.03+0.04%
DERMDermira Inc+1.15+3.52%
ACHNAchillion Pharmaceut...+0.17+2.14%
Data as of 3:59pm ET, 09/30/2016

Financials

Next reporting dateNovember 3, 2016
EPS forecast (this quarter)$0.27
Annual revenue (last year)$522.8M
Annual profit (last year)$62.9M
Net profit margin12.03%

Profile

Sector
Health Technology
Industry
Biotechnology
President, CEO &
Class III Director
Daniel J. Abdun-Nabi
CFO, Treasurer &
EVP-Corporate Services
Robert G. Kramer
Corporate headquarters
Gaithersburg, Maryland

Forecasts

Search for Jobs